Heart failure
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients meeting the diagnostic criteria for heart failure according to the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure; 2. Age >= 18 years; 3. Patients in the SGLT-2i group with documented prescriptions of SGLT-2 inhibitors (such as dapagliflozin or empagliflozin) during hospitalization or outpatient care, and patients in the historical control group receiving standard heart failure therapy without SGLT-2 inhibitors before their widespread clinical use; 4. Complete baseline data and at least one follow-up record available.
Exclusion criteria
Exclusion criteria: 1. Severe comorbidities: Patients with end-stage renal disease (eGFR < 15 mL/min/1.73 m^2), type 1 diabetes, a history of diabetic ketoacidosis (DKA), or requiring dialysis; 2. Critical missing data: Lack of core evaluation indicators (such as missing baseline or follow-up echocardiography, NT-proBNP data); cases that cannot be matched due to major differences in follow-up frequency or examination methods between the historical control group data from previous medical records and the trial group; 3. Other interference: Clinical records indicate that patients participated in other interventional drug clinical trials during the follow-up period; 4. Pregnant or breastfeeding women: Special physiological periods indicated in relevant past records.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of recurrent heart failure hospitalizations;All-cause mortality;Heart failure hospitalization; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in NT-proBNP level;Incidence of adverse events;Change in estimated glomerular filtration rate;Change in left ventricular ejection fraction; | — |
Countries
China
Contacts
Henan Provincial People's Hospital